
Novo Nordisk A/S: Rybelsus® (Oral Semaglutide 14 Mg) Demonstrates Superior Reduction In Cardiovascular Events In The ...
(MENAFN- GlobeNewsWire - Nasdaq) Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1. Data were presented at …